Correction to Figure 1 in the PANORAMA Trial Report on Intravitreal Aflibercept for Severe Nonproliferative Diabetic Retinopathy

October 1, 2026

Jama Ophthalmology

Objective:

The notice reports corrections to the PANORAMA trial report on intravitreal aflibercept for severe nonproliferative diabetic retinopathy.

Approach:

Correction: The article, initially posted online on August 5, 2021, and subsequently published in the September issue, was corrected online. The changes addressed numerical inconsistencies in Figure 1, clarified a Results time point, and corrected a typographical error in eTable 3 of Supplement 2.

Key Findings:

Numerical inconsistencies in Figure 1 were corrected.
A Results time point was specified more clearly.
A typographical error in eTable 3 of Supplement 2 was corrected.

Interpretation:

The notice reports corrections to Figure 1, the Results text, and eTable 3 of Supplement 2.

Limitations:

The context does not provide the corrected numerical values or the revised time-point wording.

Conclusion:

The PANORAMA trial report was corrected online to address numerical inconsistencies in Figure 1, clarify a Results time point, and correct a typographical error in eTable 3 of Supplement 2.

Correction to Figure 1 in the PANORAMA Trial Report on Intravitreal Aflibercept for Severe Nonproliferative Diabetic Retinopathy

Objective:

Approach:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Error in Figure 1

Related Content

FDA clears targeted cholangiocarcinoma therapy

Success of femtosecond laser-assisted deep anterior lamellar keratoplasty (Femto-DALK): a clinical case series of 42 eyes using an intraoperative optical coherence tomography (iOCT)-guided laser-generated pre-descemet tunnel

Case links red light mask to secondary glaucoma